Lilly Treatment Slows Alzheimer’s Course in Some Patients

Eli Lilly & Co. said its experimental Alzheimer’s treatment slowed the decline of cognition in some patients while failing to meet the primary goals of two large trials. The shares rose.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.